Vnitr Lek 2010, 56(11):1138-1141

Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in atrial fibrillation

M. J. Levine*, P. Schweitzer
Division of Cardiology, Department of Medicine, Beth Israel Medical Center, New York, N. Y., USA

Atrial fibrillation is the most prevalent clinically relevant arrhythmia; a major cause of morbidity and hospitalization. Additionally, atrial fibrillation carries a significant risk of thrombo-embolic events, specifically cerebrovascular accident. Among the most prevalent risk factors for atrial fibrillation, hypertension not only has the strongest correlation but is also the most prevalent. The renin-angiotensin-aldosterone system represents a prime target for the treatment of hypertension through the use of angiotensin-converting enzymes inhibitors and angiotensin II receptor blockers. In addition to blood pressure control, these medications have been shown to reduce the occurrence of atrial fibrillation. They have been shown to have effects at the cellular level in preventing atrial fibrosis. Additionally, these medications may prevent the development of atrial fibrillation, reduce the duration of atrial fibrillation, and facilitate electrical cardioversion in patients with the arrhythmia. Therefore, patients with, or at risk for atrial fibrillation may benefit from treatment with renin-angiotensin-aldosterone system antagonists; deriving benefits from these medications beyond simple blood pressure control.

Keywords: angiotensin-converting enzymes inhibitors; angiotensin II receptor blockers; atrial fibrillation; renin-angiotensin-aldosterone system antagonists; cerebrovascular accident

Received: June 6, 2010; Published: November 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Levine MJ, Schweitzer P. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in atrial fibrillation. Vnitr Lek. 2010;56(11):1138-1141.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Fuster V, Rydén L, Cannom D et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation a report of the American College of Cardiology/American Heart Associate task force of practice guidelines and the European Society of Cardiology committee for practice guidelines: developed in collaboration with the European Heart Rhythm Associate then the Heart Rhythm Society. Circulation 2006; 114: 257-354. Go to original source... Go to PubMed...
    2. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375. Go to original source... Go to PubMed...
    3. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-952. Go to original source... Go to PubMed...
    4. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833. Go to original source... Go to PubMed...
    5. Krahn AD, Manfreda J, Tate RB et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-484. Go to original source... Go to PubMed...
    6. Kannel WB, Wolf PA, Benjamin EJ et al. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N. Go to original source... Go to PubMed...
    7. Allessie M, Ausma J, Schotten U. Electrical, contractile, and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54: 230-246. Go to original source... Go to PubMed...
    8. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complication and potential therapeutic target. Am J Cardiol 2003; 91: 9G-14G. Go to original source... Go to PubMed...
    9. Miyasaka Y, Barnes M, Gersh B et al. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980-2000. Stroke 2005; 36: 2362-2366. Go to original source... Go to PubMed...
    10. Chapman N, Huxley R, Anderson C et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS trial. Stroke 2004; 35: 116-121. Go to original source... Go to PubMed...
    11. Kumagai K, Nakashima H, Urata H et al. Effects on angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-2204. Go to original source... Go to PubMed...
    12. McEwan PE, Gray GA, Sherry L et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998; 98: 2765-2773. Go to original source... Go to PubMed...
    13. Makkar K, Sanoski CA, Spinler S. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy 2009; 29: 31-48. Go to original source... Go to PubMed...
    14. Garg S, Narula J, Marelli C et al. Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias. Am J Cardiol 2006; 97: 921-925. Go to original source... Go to PubMed...
    15. Neuberger HR, Schotten U, Verheule S et al. Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation 2005; 111: 30-37. Go to original source... Go to PubMed...
    16. Schaer BA, Schneider C, Jick SS et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 2010; 152: 78-84. Go to original source... Go to PubMed...
    17. Verdecchia P, Reboldi G, Gattobigio R et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41: 218-223. Go to original source... Go to PubMed...
    18. Heckbert SR, Wiggins KL, Glazer NL et al. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. Am J Hypertens 2009; 22: 538-544. Go to original source... Go to PubMed...
    19. Hansson L, Lindholm L, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611-616. Go to original source... Go to PubMed...
    20. Hansson L, Lindholm L, Ekbom T et al. Randomised trial of old and new hypertensive drugs in elderly patients: cardiovascular morbidity and mortality the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756. Go to original source... Go to PubMed...
    21. Schmieder RE, Kjeldsen SE, Julius S et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertension 2008; 26: 403-411. Go to original source... Go to PubMed...
    22. Watchell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719. Go to original source... Go to PubMed...
    23. Salehian O, Healey J, Stambler B et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Protection Evaluation (HOPE) study. Am Heart J 2007; 154: 448-453. Go to original source... Go to PubMed...
    24. Yusuf S, Teo K, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. Go to original source... Go to PubMed...
    25. Ueng KC, Tsai TP, Yu WC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Eur Heart J 2003; 24: 2090-2098. Go to original source... Go to PubMed...
    26. Madrid AH, Bueno MG, Rebollo JM et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation 2002; 106: 331-336. Go to original source... Go to PubMed...
    27. Belluzzi F, Sernesi L, Preti P et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009; 53: 24-29. Go to original source... Go to PubMed...
    28. Van Noord T, Crijns H, van den Berg M et al. Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation. BMC Cardiovasc Disord 2005; 5: 3. Go to original source... Go to PubMed...
    29. Healey J, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.